Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study

INTRODUCTION: Global multidrug-resistant tuberculosis (MDR-TB) treatment success rates remain suboptimal. Highly active WHO group A drugs moxifloxacin and levofloxacin show intraindividual and interindividual pharmacokinetic variability which can cause low drug exposure. Therefore, therapeutic drug...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Elsen, Simone HJ, Sturkenboom, Marieke GG, Akkerman, Onno, Barkane, Linda, Bruchfeld, Judith, Eather, Geoffrey, Heysell, Scott K, Hurevich, Henadz, Kuksa, Liga, Kunst, Heinke, Kuhlin, Johanna, Manika, Katerina, Moschos, Charalampos, Mpagama, Stellah G, Muñoz Torrico, Marcela, Skrahina, Alena, Sotgiu, Giovanni, Tadolini, Marina, Tiberi, Simon, Volpato, Francesca, van der Werf, Tjip S, Wilson, Malcolm R, Zúñiga, Joaquin, Touw, Daan J, Migliori, Giovanni B, Alffenaar, Jan-Willem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304807/
https://www.ncbi.nlm.nih.gov/pubmed/32554740
http://dx.doi.org/10.1136/bmjopen-2019-035350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304807/
https://www.ncbi.nlm.nih.gov/pubmed/32554740
http://dx.doi.org/10.1136/bmjopen-2019-035350

Ejemplares similares